09:17 AM EDT, 10/07/2025 (MT Newswires) -- Health care stocks were declining pre-bell Tuesday, with the Health Care Select Sector SPDR Fund ( XLV ) 0.2% lower and the iShares Biotechnology ETF (IBB) down 0.1%.

Dyne Therapeutics ( DYN ) shares were up more than 2% after the company said additional one-year data from its ongoing phase 1/2 trial of zeleciment basivarsen, or z-basivarsen, in patients with myotonic dystrophy type 1 demonstrated "clinically meaningful improvements" in strength and function using the selected registrational dose.

Mesoblast (MESO) stock was up more than 2% after the company said Ryoncil sales generated $21.9 million in gross revenue for the quarter through Sept. 30, up 66% sequentially.

Novo Nordisk ( NVO ) on Monday lost its appeal against the US Government's Medicare Drug Price Negotiation Program that gives it the power to reduce prices of prescription drugs. Separately, Reuters reported that Novo Nordisk ( NVO ) has laid off numerous workers at its Clayton, North Carolina, the site that produces semaglutides used in its weight-loss and diabetes drugs Wegovy and Ozempic. Shares of Novo Nordisk ( NVO ) were marginally lower premarket.